Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis

Figure 3 Oral treatment with plecanatide ameliorates colitis in acute and chronic mouse models. A: Acute colitis examined in BALB/c mice (n = 5-8/group) was induced by rectal instillation of TNBS. Mice were administered an oral gavage of vehicle or plecanatide (0.5 and 2.5 mg/kg per day) starting on 0 d; animals were euthanized on 7^th day and colitis scores were determined; B: TCRα^-/- mice, a model for chronic spontaneous colitis, were administered an oral gavage of plecanatide (0.5 and 2.5 mg/kg) or vehicle for 14 d. At the end of the study, colon tissues were harvested and used for histopathological analysis to assess colitis. Results are depicted as mean colitis score ± SD. TCRα: T-cell receptor alpha; TNBS: 2, 4, 6-trinitrobenzenesulfonic acid sol.